The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
The esteemed duo perfectly embody the brand's core values of family, love, and the special bond we share with our pets
Almost 300 million people globally have chronic hepatitis B
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Total transaction value of the divestment is Rs. 3,660 million
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Subscribe To Our Newsletter & Stay Updated
